VRTX as reported
Vertex Pharmaceuticals reported $12.6B of revenue over the trailing twelve months, +10% on the year before. 11 reported series are charted on this page, each one as filed.
$12.6B
Revenue, trailing twelve months · to Q2 2026 · +10% against the twelve months before
- Net Income
- $4.41B
Net Income · +21% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $3.80B
Free Cash Flow · +8.5% year on year · trailing twelve months to Q2 2026
- Op Margin
- 38%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $12.6B | +10% | Q2 2026 |
| Net Income | $4.41B | +21% | Q2 2026 |
| EPS | $17.17 | +22% | Q2 2026 |
| Gross Margin | 86% | n/a | Q2 2026 |
| Op Margin | 38% | n/a | Q2 2026 |
| Net Margin | 35% | n/a | Q2 2026 |
| ROE | 22% | n/a | Q2 2026 |
| ROA | 16% | n/a | Q2 2026 |
| ROIC | 2582% | n/a | Q4 2017 · 34 quarters behind |
| Free Cash Flow | $3.80B | +8.5% | Q2 2026 |
| P/E | 31.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Vertex Pharmaceuticals (VRTX) - Revenue & ProfitRevenue & ProfitVertex Pharmaceuticals (VRTX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com